Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2019 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update

Major clinical progress with four differentiated therapeutic programs in immuno-oncology and autoimmune diseases;Received €25 M in milestones from collaborations with Servier and Boehringer...
September 05, 2019 11:40 ET | Source: Oxurion NV

Oxurion NV Business Update – H1 2019

Positive Topline Phase 1 Results with THR-149 (Plasma Kallikrein Inhibitor) for treatment of DME Mixed Topline Results from exploratory THR-317 (anti-PlGF) Phase 2a ranibizumab combination...
September 05, 2019 10:03 ET | Source: Research and Markets

$17.33 Billion Neutropenia Treatment Market Outlook, 2019-2027 - Pipeline Seems Promising with Products Present in Phase III of Clinical Trials

Dublin, Sept. 05, 2019 (GLOBE NEWSWIRE) -- The "Global Neutropenia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
September 05, 2019 09:45 ET | Source: BioRestorative Therapies, Inc.

BioRestorative Therapies’ Stockholders Approve Institutional Investor Agreement and Exchange Agreements

MELVILLE, N.Y., Sept. 05, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that, at...
September 05, 2019 09:05 ET | Source: Aqua Metals

Aqua Metals Achieves Another Record Month of Production in August

MCCARRAN, Nev., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), which is reinventing lead recycling with its AquaRefining™ technology, today announced that its operations team...
September 05, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
September 05, 2019 07:30 ET | Source: Scholar Rock

Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
September 05, 2019 07:00 ET | Source: Yamana Gold

Yamana Gold Increases Reserve Grade, Significantly Increases Reserves and Announces Further Positive Exploration Results at Jacobina Mine

TORONTO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- YAMANA GOLD INC. (TSX:YRI; NYSE:AUY) (“Yamana” or “the Company”) announces updated mid-year mineral reserve and mineral resource estimates for the...
September 05, 2019 07:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)

DUBLIN, Ireland, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
September 05, 2019 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

- Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions – - New Data Presented Today at the Society for...